Eikon Therapeutics Inc(EIKN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:29 PM ET (Korea 10/31 07:29)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 53.39% | Shs Outstand | 54.1M | Perf Week | -26.86% |
| Market Cap | 0.29B | Forward P/E | - | EPS next Y | -4.37% | Insider Trans | 0.31% | Shs Float | 25.3M | Perf Month | -28.34% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -1.7 | Inst Own | 42.07% | Short Float | 25.23% | Perf Quarter | -41.97% |
| Income | - | P/S | - | EPS this Y | 93.95% | Inst Trans | 1.03% | Short Ratio | 11.54 | Perf Half Y | -45.14% |
| Sales | - | P/B | 0.62 | EPS next 5Y | 63.64% | ROA | - | Short Interest | 6.37M | Perf YTD | -68.86% |
| Book/sh | 8.62 | P/C | 0.54 | EPS past 3/5Y | -13.35% - | ROE | - | 52W High | -69.48% ($17.40) | Perf Year | - |
| Cash/sh | 9.81 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 0.57% ($5.28) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 14.2% 9.78% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.69 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.89 | EPS Q/Q | -10.51% | Profit Margin | - | RSI (14) | 28.15 | Recom | 1.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.89 | Sales Q/Q | - | SMA20 | -24.24% ($7.01) | Beta | - | Target Price | $24.33 |
| Payout | - | Debt/Eq | 0.54 | Earnings | 2026/8/13 | SMA50 | -38.19% ($8.59) | Rel Volume | 1 | Prev Close | $5.35 |
| Employees | - | LT Debt/Eq | 0.52 | EPS/Sales Surpr. | -2.84% - | SMA200 | -49.09% ($10.43) | Avg Volume(3M) | 0.55M | Price | $5.31 |
| IPO | 2026/2/5 | Option/Short | No/Yes | Trades | 3604 | Volume | 553,138 | Change | -0.75% |
🔬 A clinical-stage biopharmaceutical company developing next-generation anticancer drugs and other novel therapeutics based on innovative single-molecule tracking technology. By analyzing the subtle movements of proteins within living cells in real time—something that was difficult to capture with conventional technologies—the company is identifying unique drug targets and creating differentiated value through the proven expertise of its experienced management team.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +94.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #268 of 597 in the industry
Based on market cap of $288M.
VOGX#266 Vogenx Inc $301M PER - 
SCTX#267 Scribe Therapeutics Inc $292M PER - EIKN#268 Eikon Therapeutics Inc $288M PER - 
FULC#269 Fulcrum Therapeutics Inc $283M PER - 
VCRE#270 Vicore Pharma Holding AB ADR $276M PER - 
FAQ
What kind of company is EIKN?
EIKN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EIKN?
The market cap of EIKN is approximately $288M, ranking 3,683 within its sector.
What is the 52-week high and low for EIKN?
EIKN has recorded a 52-week high of $17.40 and a low of $5.28.
